BCN Peptides participates in a collaborative research project targeting new therapeutic solutions for rare diseases (AMMIC).
The objective of the project is to create a technological cluster, with several SMEs having as common goal to accelerate the research, to afford efficient and competitive pharmaceutical solutions to rare diseases.
The project, enclosed in the RIS3CAT NextHealth comunity from ACCIÒ, is cofinanced with the European Union FEDER funds. The consortium that includes seven SMEs invests 2,47 M euros in this research field.
BCN Peptides participates in the project with a new peptide targeting metastatic rhabdomyosarcoma, a project initiated in collaboration with the VHIR Foundation.